DGAP-News: Biofrontera AG:
DGAP-News: Biofrontera AG
/ Key word(s): Miscellaneous
Biofrontera announces conference call to be held on April 21, 2020 to discuss full year 2019 financial results Leverkusen, Germany, April 9, 2020 - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Conference calls for shareholders and interested investors will be held on Tuesday, April 21, 2020, at the following times: In German, April 21, 2020 at 10:00 am CEST (4:00 am EST) In English, April 21, 2020 at 2:00 pm CEST (8:00 am EST) Please dial in 10 minutes ahead of time to ensure a timely start of the conference call.
About Biofrontera: Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics. The Germany-based company, with almost 200 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company's lead product is the combination of Ameluz(R), a topical prescription drug, and medical device BF-RhodoLED(R) for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz(R) has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets the prescription medication XepiTM for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos(R), which offers specialized care for damaged or diseased skin. Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ.www.biofrontera.com.
09.04.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | Biofrontera AG |
Hemmelrather Weg 201 | |
51377 Leverkusen | |
Germany | |
Phone: | +49 (0)214 87632 0 |
Fax: | +49 (0)214 87632 90 |
E-mail: | [email protected] |
Internet: | www.biofrontera.com |
ISIN: | DE0006046113, NASDAQ: BFRA |
WKN: | 604611 |
Listed: | Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Munich, Stuttgart, Tradegate Exchange; Nasdaq |
EQS News ID: | 1020107 |
End of News | DGAP News Service |
|
1020107 09.04.2020